A new scientific avenue for daridorexant: Idorsia to advance development in autism spectrum disorder
Idorsia Ltd (SIX: IDIA) is advancing a new development program to investigate daridorexant in autism spectrum disorder (ASD).
Read the full story on GlobeNewswire → Opens the original article on www.globenewswire.comSummary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.